Cat. No.: HY-N0452

Hyperoside

(Synonyms: Quercetin 3-O-galactoside; Quercetin 3-O-β-D-galactopyranoside)

26 Cited Publications

Customer Review

Based on 26 publication(s) in Google Scholar

Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis.

For research use only. We do not sell to patients.

Purity: 99.71%
CAS No.: 482-36-0
Formula: C₂₁H₂₀O₁₂
Molecular Weight:464.38

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Hyperoside Chemical Structure

CAS No.: 482-36-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (26)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μg/mL Compound: Compound 7	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25862199]
C2C12	EC₅₀	60.5 μM Compound: 11	Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting	[PMID: 22738356]
HeLa	IC₅₀	>10 μg/mL Compound: Compound 7	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25862199]
MDCK	CC₅₀	>431 μM Compound: Hyperoside	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 25096296]
RAW264.7	IC₅₀	>50 μM Compound: 16	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA	[PMID: 24679441]
RAW264.7	IC₅₀	48.8 μM Compound: 16	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis	[PMID: 24679441]
SGC-7901	IC₅₀	>10 μg/mL Compound: Compound 7	Cytotoxicity against human SGC7901 cells by MTT assay Cytotoxicity against human SGC7901 cells by MTT assay	[PMID: 25862199]

In Vitro

Hyperoside (12.5-100 μM; 6-24 h) inhibits MCF-7 and 4T1 cell growth^[2].
Hyperoside (25-100 μM; 24 h) induces apoptosis of breast cancer cells^[2].
Hyperoside inhibits the activation of the NF-κB signaling pathway via the attenuation of intracellular ROS generation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

MCF-7 and 4T1 cells
Concentration:

12.5, 25, 50, 75, or 100 µM
Incubation Time:

6, 12, or 24 h
Result:

Inhibited cell growth in a time- and concentration-dependent manner.

Apoptosis Analysis^[2]

Cell Line:

MCF-7 and 4T1 cells
Concentration:

25, 50 and 100 µM
Incubation Time:

24 h
Result:

Increased the expressions of Bax, cleaved caspase-3 and cleaved PARP, and decreased Bcl-2 in mRNA and protein levels.

In Vivo

Hyperoside (intraperitoneal injection; 50 mg/kg; every two day for 18 days) treatment inhibits breast tumor growth in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c mice injected with 4T1 cells^[2]
Dosage:

50 mg/kg
Administration:

Intraperitoneal injection; 50 mg/kg; every two day for 18 days
Result:

Reduced the average tumor volume compared to the control group.
Decreased Bcl-2 and increased bax and cleaved caspase-3.

Chemical Information

CAS No. 482-36-0
Appearance Solid
Molecular Weight 464.38
Formula C₂₁H₂₀O₁₂
Color Light yellow to yellow
SMILES

OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1
Synonyms

Quercetin 3-O-galactoside; Quercetin 3-O-β-D-galactopyranoside
Structure Classification
- Flavonoids
- Flavonols
- Phenols
- Polyphenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (26)

All Cell Imaging/StainingRT-PCRHistological Imaging/StainingELISAIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Engineering

2026 May 20.
Phytomedicine

Hyperoside accelerates myelin debris clearance by inhibiting signal transducer and activator of transcription 3 phosphorylation in peripheral nerve injury. [Abstract]

2026 Jul:156:158214. PMID: 42025010
Phytomedicine

Hyperoside stabilizes ACAT1 to promote fatty acid oxidation and attenuate kidney fibrosis via the L-carnitine-SIRT3 axis. [Abstract]

2026 Jun:155:158080. PMID: 41903436
Phytomedicine

Hyperoside as a promising multi-target candidate for neovascular age-related macular degeneration. mechanisms involving Wnt/β-catenin signaling, oxidative stress, and inflammation suppression. [Abstract]

2026 Apr:153:157952. PMID: 41720012
Phytomedicine

Protective effects of E Se tea extracts against alcoholic fatty liver disease induced by high fat/alcohol diet: In vivo biological evaluation and molecular docking study. [Abstract]

2022 Jul:101:154113. PMID: 35490493
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 Oct 15:489:144992. PMID: 40466530
Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
Chin Med

Hyperoside protects against poly-GR-mediated neurodegeneration via regulation of mitochondrial fission and oxidative stress in C9orf72-associated ALS. [Abstract]

2026 Jun 4;21(1):161. PMID: 42243993
J Agric Food Chem

High-Pressure and Thermal Pasteurization Applied to Smoothies Enhances (Poly)Phenol Bioaccessibility along the Gastrointestinal Tract. [Abstract]

2025 Jun 25;73(25):15561-15578. PMID: 40497562
Ind Crops Prod

2026 May 8;246:123392.
Ind Crops Prod

2025 Dec 11;239:122458.
Life Sci

Hyperoside mitigates PCOS-associated adipogenesis and insulin resistance by regulating NCOA2-mediated PPAR-γ ubiquitination and degradation. [Abstract]

2025 Mar 1:364:123417. PMID: 39880157

Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]

Hyperoside (HPS) (10 μM; 8 d) significantly inhibited the lipid accumulation induced by MDI in SVF and 3 T3-L1 cells.

Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]

Hyperoside (HPS) (10 μM; 8 d) effectively restored the expressions of C/EBPα and FABP4 in SVF and 3 T3-L1 cells to levels comparable to the control.

Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]

Low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) and high-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatment markedly decreased the number of cystic follicles in polycystic ovary syndrome (PCOS) mice.

Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]

High-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatment effectively reversed changes of FSH, LH, progesterone, and testosterone in polycystic ovary syndrome (PCOS) mice, while low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) improved all hormone levels except FSH.

Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]

Both low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) and high-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatments led to a reduction in fasting serum glucose levels and improved insulin sensitivity in polycystic ovary syndrome (PCOS) mice.
Foods

Design of a Plant-Based Smoothie: Exploiting Ingredient Complementarity for a Diversified (Poly)phenolic Profile Quantified by Targeted LC-MS/MS Analysis. [Abstract]

2026 Apr 9;15(8):1293. PMID: 42073181
Front Pharmacol

Hyperoside alleviates myocardial ischemia-reperfusion injury in heart transplantation by promoting mitochondrial fusion via activating the Stat3-Tom70-Opa1 pathway. [Abstract]

2025 Sep 4:16:1566674. PMID: 40978492
Molecules

Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening. [Abstract]

2026 Mar 5;31(5):864. PMID: 41828851
Mol Med Rep

Hyperoside prevents osteoporosis by activating the PI3K/AKT signaling pathway to inhibit oxidative stress and promote osteogenesis. [Abstract]

2026 Feb;33(2):57. PMID: 41347823
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
Neuropharmacology

Hyperoside ameliorates neuropathic pain by modulating the astroglial reactivity in the vlPAG. [Abstract]

2025 Mar 15:266:110276. PMID: 39716641
Brain Res Bull

Hyperoside alleviates macrophages and microglia-mediated neuroinflammation and oxidative stress through activating PI3K/AKT and Nrf2/HO-1 signaling pathway post spinal cord injury. [Abstract]

2025 Nov:232:111618. PMID: 41192740
Toxicol Appl Pharmacol

Hyperoside impairs mitochondrial respiration in chronic myeloid leukemia by promoting STUB1-mediated ubiquitination and degradation of NOX4. [Abstract]

2026 Mar 11:511:117795. PMID: 41825841
PeerJ

Hyperoside alleviates doxorubicin-induced myocardial cells apoptosis by inhibiting the apoptosis signal-regulating kinase 1/p38 pathway. [Abstract]

2023 May 18:11:e15315. PMID: 37220525
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Pol J Microbiol

Hyperoside Alleviates Helicobacter pylori-Induced Gastric Epithelial Cell Injury by Regulating Nrf2/HO-1 Signaling. [Abstract]

2025 Mar 26;74(1):60-70. PMID: 40146790
Pharmacogn Mag

2025 Jan 5.
Univerzita Karlova v Praz

2021 Oct.

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (269.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1534 mL

10.7670 mL

21.5341 mL

5 mM

0.4307 mL

2.1534 mL

4.3068 mL

10 mM

0.2153 mL

1.0767 mL

2.1534 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (21.53 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li S, et al. Antifungal activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca acuminata. J Agric Food Chem. 2005 Jan 12;53(1):32-7. [Content Brief]

[2]. Qiu J, et al. Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway. Int J Mol Sci. 2019 Dec 24;21(1):131. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1534 mL	10.7670 mL	21.5341 mL	53.8352 mL
	5 mM	0.4307 mL	2.1534 mL	4.3068 mL	10.7670 mL
	10 mM	0.2153 mL	1.0767 mL	2.1534 mL	5.3835 mL
	15 mM	0.1436 mL	0.7178 mL	1.4356 mL	3.5890 mL
	20 mM	0.1077 mL	0.5384 mL	1.0767 mL	2.6918 mL
	25 mM	0.0861 mL	0.4307 mL	0.8614 mL	2.1534 mL
	30 mM	0.0718 mL	0.3589 mL	0.7178 mL	1.7945 mL
	40 mM	0.0538 mL	0.2692 mL	0.5384 mL	1.3459 mL
	50 mM	0.0431 mL	0.2153 mL	0.4307 mL	1.0767 mL
	60 mM	0.0359 mL	0.1795 mL	0.3589 mL	0.8973 mL
	80 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6729 mL
	100 mM	0.0215 mL	0.1077 mL	0.2153 mL	0.5384 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Hyperoside

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Hyperoside

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (26)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Hyperoside Related Classifications

HY-N0452 Related Classifications